Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janusz Emerich

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Ginekologia Polska|February 27, 2003
[The incidence of human papilloma virus (HPV) DNA in patients with cervical carcinoma from Gdansk region]Joanna Liss, Krzysztof Łukaszuk, Jacek Gulczyński, et al.
Ginekologia Polska|May 2, 2003
[Comparison of quality of life in patients with advanced ovarian cancer treated with intraperitoneal or intravenous cisplatin and cyclophosphamide as a second line of therapy]Ewa Majdak, Liliana Krasińska, Piotr Mielcarek, et al.
Clinical Biochemistry|February 5, 2008
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancerJoanna Narkiewicz, Dagmara Klasa-Mazurkiewicz, Dorota Zurawa-Janicka, et al.
Oncology Reports|May 9, 2009
Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancerJoanna Narkiewicz, Sylwia Lapinska-Szumczyk, Dorota Zurawa-Janicka, et al.
Przeglad Lekarski|August 30, 2007
[Late recurrence of malignant tumours 20 years after diagnosis and treatment]Zygmunt Chodorowski, Jacek Sein Anand, Jacek Jassem, et al.
Hereditary Cancer in Clinical Practice|March 13, 2010
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian TumoursIzabela Brozek, Iwona Kardaś, Karolina Ochman, et al.
Gynecologic Oncology|November 13, 2007
High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in PolandIzabela Brozek, Karolina Ochman, Jarosław Debniak, et al.
Cancer|July 28, 2005
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinomaEwa Joanna Majdak, Jaroslaw Debniak, Tomasz Milczek, et al.
Contraception|November 17, 2009
Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trialAlexander Teichmann, Dan Apter, Janusz Emerich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancerIgnace B Vergote, Radoslav Chekerov, Frederic Amant, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Ginekologia Polska|February 27, 2003
[The incidence of human papilloma virus (HPV) DNA in patients with cervical carcinoma from Gdansk region]Joanna Liss, Krzysztof Łukaszuk, Jacek Gulczyński, et al.
Ginekologia Polska|May 2, 2003
[Comparison of quality of life in patients with advanced ovarian cancer treated with intraperitoneal or intravenous cisplatin and cyclophosphamide as a second line of therapy]Ewa Majdak, Liliana Krasińska, Piotr Mielcarek, et al.
Clinical Biochemistry|February 5, 2008
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancerJoanna Narkiewicz, Dagmara Klasa-Mazurkiewicz, Dorota Zurawa-Janicka, et al.
Oncology Reports|May 9, 2009
Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancerJoanna Narkiewicz, Sylwia Lapinska-Szumczyk, Dorota Zurawa-Janicka, et al.
Przeglad Lekarski|August 30, 2007
[Late recurrence of malignant tumours 20 years after diagnosis and treatment]Zygmunt Chodorowski, Jacek Sein Anand, Jacek Jassem, et al.
Hereditary Cancer in Clinical Practice|March 13, 2010
HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian TumoursIzabela Brozek, Iwona Kardaś, Karolina Ochman, et al.
Gynecologic Oncology|November 13, 2007
High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in PolandIzabela Brozek, Karolina Ochman, Jarosław Debniak, et al.
Cancer|July 28, 2005
Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinomaEwa Joanna Majdak, Jaroslaw Debniak, Tomasz Milczek, et al.
Contraception|November 17, 2009
Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trialAlexander Teichmann, Dan Apter, Janusz Emerich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancerIgnace B Vergote, Radoslav Chekerov, Frederic Amant, et al.
Pageof 9